» Articles » PMID: 28592247

Immunization with a DNA Vaccine Encoding Toxoplasma Gondii Superoxide Dismutase (TgSOD) Induces Partial Immune Protection Against Acute Toxoplasmosis in BALB/c Mice

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2017 Jun 9
PMID 28592247
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Toxoplasma gondii (T. gondii) is an obligate intracellular protozoan parasite that infects all warm-blooded animals including humans and causes toxoplasmosis. An effective vaccine could be an ideal choice for preventing and controlling toxoplasmosis. T. gondii Superoxide dismutase (TgSOD) might participate in affecting the intracellular growth of both bradyzoite and tachyzoite forms. In the present study, the TgSOD gene was used to construct a DNA vaccine (pEGFP-SOD).

Methods: TgSOD gene was amplified and inserted into eukaryotic vector pEGFP-C1 and formed the DNA vaccine pEGFP-SOD. Then the BALB/c mice were immunized intramuscularly with the DNA vaccine and those injected with pEGFP-C1, PBS or nothing were treated as controls. Four weeks after the last immunization, all mouse groups followed by challenging intraperitoneally with tachyzoites of T. gondii ME49 strain.

Results: Results showed higher levels of total IgG, IgG2α in the sera and interferon gamma (IFN-γ) in the splenocytes from pEGFP-SOD inoculated mice than those unvaccinated, or inoculated with either empty plasmid vector or PBS. The proportions of CD4 T cells and CD8 T cells in the spleen from pEGFP-SOD inoculated mice were significantly (p < 0.05) increased compared to control groups. In addition, the survival time of mice immunized with pEGFP-SOD was significantly prolonged as compared to the controls (p < 0.05) although all the mice died.

Conclusion: The present study revealed that the DNA vaccine triggered strong humoral and cellular immune responses, and aroused partial protective immunity against acute T. gondii infection in BALB/c mice. The collective data suggests the SOD may be a potential vaccine candidate for further development.

Citing Articles

spores displaying GRA12 induce immunity against acute toxoplasmosis.

Sun H, Yuan X, Zhou W, Zhou Z, Su F, Fu Y Front Immunol. 2025; 16:1457560.

PMID: 40079011 PMC: 11897052. DOI: 10.3389/fimmu.2025.1457560.


Ivermectin modulated cerebral γ-aminobutyric acid (GABA) and reduced the number of chronic cysts significantly in the brains of immunocompromised mice.

Ahmed Fahmy M, Shalaby M, Issa R, Badawi M, Magdy M, Afife A J Parasit Dis. 2023; 47(3):635-643.

PMID: 37520203 PMC: 10382416. DOI: 10.1007/s12639-023-01608-4.


REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Warner R, Chapman R, Davis B, Davis P J Parasitol. 2021; 107(6):882-903.

PMID: 34852176 PMC: 8638329. DOI: 10.1645/20-157.


With Chitosan and PLGA as the Delivery Vehicle, Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice.

Yu Z, Cao W, Gao X, Aleem M, Liu J, Luo J Front Immunol. 2021; 12:726615.

PMID: 34512659 PMC: 8430031. DOI: 10.3389/fimmu.2021.726615.


Evaluation of CpG-ODN-Adjuvanted Virus-Like Particle Vaccine upon One, Two, and Three Immunizations.

Kang H, Chu K, Kim M, Park H, Jin H, Lee S Pharmaceutics. 2020; 12(10).

PMID: 33086673 PMC: 7588908. DOI: 10.3390/pharmaceutics12100989.


References
1.
Renault J, Viscogliosi E, Toursel C, Briche I, Engels A, Lepage G . Molecular cloning, expression analysis and iron metal cofactor characterisation of a superoxide dismutase from Toxoplasma gondii. Mol Biochem Parasitol. 2000; 106(1):121-9. DOI: 10.1016/s0166-6851(99)00211-x. View

2.
Dubey J, Hill D, Jones J, Hightower A, Kirkland E, Roberts J . Prevalence of viable Toxoplasma gondii in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. J Parasitol. 2006; 91(5):1082-93. DOI: 10.1645/GE-683.1. View

3.
Xu Y, Zhang N, Tan Q, Chen J, Lu J, Xu Q . Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model. BMC Infect Dis. 2014; 14:525. PMC: 4261603. DOI: 10.1186/1471-2334-14-525. View

4.
Gurunathan S, Klinman D, Seder R . DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000; 18:927-74. DOI: 10.1146/annurev.immunol.18.1.927. View

5.
Yuan Z, Ren D, Zhou D, Zhang X, Petersen E, Li X . Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model. Vaccine. 2013; 31(31):3135-9. DOI: 10.1016/j.vaccine.2013.05.040. View